Inflammatory demyelinating diseases of the central nervous system

Source: Wikipedia, the free encyclopedia.

Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process.[1][2][3] IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis,[4][5] but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.[6][7]

Multiple sclerosis for some people is a

Anti-MOG and Anti-NF spectrums.[9] A LHON-associated MS[10] has also been reported, and in addition there have been inconclusive reports of TNF-α blockers inducing demyelinating disorders.[11]

The subject is under intense research and the list of MS autoantibodies is expected to grow in the near future.[12][13][14]

Separated variants

As of 2014 several previous MS variants had been separated from MS after the discovery of a specific auto-antibody. Those autoantibodies were anti-AQP4, anti-MOG and some anti-Neurofascins.[15]

The pathogenic mechanism is usually not related to the clinical course. Therefore, one given pathogenic underlying condition can yield several clinical diseases, and one disease can be produced by several pathogenic conditions.[citation needed]

These conditions can appear as

neuromyelitis optica or acute disseminated encephalomyelitis.[17]

Anti-AQP4 spectrum

See Anti-AQP4 diseases

Originally found in

neuromyelitis optica
, this autoantibody has been associated with other conditions. Its current spectrum is as following:

Anti-MOG spectrum

See
Anti-MOG associated encephalomyelitis

Anti-MOG associated spectrum, often clinically presented as an anti-MOG autoimmune encephalomyelitis,[21][22] but can also appear as negative NMO or atypical multiple sclerosis.[23]

The presence of anti-MOG autoantibodies has been associated with the following conditions[24]

  • Some cases of aquaporin-4-seronegative neuromyelitis optica: NMO derived from an antiMOG associated encephalomyelitis,[22]
  • Some cases of acute disseminated encephalomyelitis, specially the recurrent ones (MDEM)[25]
  • Some cases of McDonalds-positive multiple sclerosis[24][26][23][27]
  • isolated optic neuritis or transverse myelitis[24]
  • Recurrent optic neuritis. The repetition of an idiopatic optic neuritis is considered a distinct clinical condition, and it has been found to be associated with anti-MOG autoantibodies[28]
    • CRION (
      Chronic relapsing inflammatory optic neuritis): A distinct clinical entity from other inflammatory demyelinating diseases.[29] Some reports consider it a form of Anti-MOG encephalomyelitis[30] and the most recent ones consider it the main phenotype of the anti-MOG spectrum[31]

The anti-mog spectrum in children is equally variated: Out of a sample of 41 children with MOG-antibodies 29 had clinical NMOSD (17 relapsing), 8 had ADEM (4 relapsing with ADEM-ON), 3 had a single clinical event CIS, and 1 had a relapsing tumefactive disorder. Longitudinal myelitis was evident on MRI in 76[percent]. It has also been noted that percentage of children with anti-mog antibodies respect a demyelinating sample is higher than for adults[32]

Some NMO patients present double positive for autoantibodies to AQP4 and MOG. These patients have MS-like brain lesions, multifocal spine lesions and retinal and optic nerves atrophy.[33]

Anti-neurofascin spectrum

See Anti-neurofascin demyelinating diseases

Some anti-

neurofascin demyelinating diseases were previously considered a subtype of Multiple Sclerosis but now they are considered a separate entity, as it happened before to anti-MOG and anti-AQP4 cases. Around 10% of MS cases are now thought to be anti-Neurofascin disease in reality.[34]

Anti-neurofascin autoantibodies have been reported in atypical cases of MS and

CIDP, and a whole spectrum of Anti-neurofascin demyelinating diseases has been proposed.[35]

Some cases of CIDP are reported to be produced by auto-antibodies against several

neurofascin proteins. These proteins are present in the neurons and four of them have been reported to produce disease: NF186, NF180, NF166 and NF155.[35]

Antibodies against

Neurofascins NF-155 can also appear in MS[36] and NF-186 could be involved in subtypes of MS[37]
yielding an intersection between both conditions.

Summarising, autoantibodies against several neurofascins can produce MS: neurofascin186 (NF186), neurofascin155 (NF155), contactin 1 (CNTN1), contactin associated protein 1 (CASPR1) and gliomedin. All of them nodal and paranodal proteins.[35]

Demyelination associated with anti-TNF therapy

Main article: TNF inhibitor

Several anti-TNF drugs like adalimumab[38][39] are commonly prescribed by a number of autoimmune conditions. Some of them have been reported to produce a CNS-demyelination compatible with standard MS.[11][40][41] Several other monoclonal antibodies like pembrolizumab,[42] nivolumab[43] and infliximab[44] have been also reported to produce MS as an adverse event.[45][11] Nevertheless, it is not so similar as reported in the previous references.[46][improper synthesis?][clarification needed]

The reactions following Anti-TNF therapy have been diverse according to the source of the disease.[40][41][43][failed verification] Some of these cases can be classify as ADEM, using the confluent demyelination as barrier between both conditions.[47][non-primary source needed]

In most cases, the damage fulfills all pathological diagnostic criteria of MS and can therefore be classified as MS in its own right.[

Dawson fingers,[41][improper synthesis?
] which is supposed to be a MS-only feature.

These recent problems with artificial anti-

tumor necrosis factor alpha involvement in some multiple sclerosis variants.[medical citation needed
]

LHON-associated MS

Also a previous subtype of MS associated to LHON has been described (LHON-MS)[10] It is a presentation of LHON with MS-like CNS damage.

It used to satisfy McDonalds definition for MS, but after demonstration that LHON can produce this kind of lesions, the "no better explanation" requirement does not hold anymore. It is not due to auto-antibodies, but to defective mitochondria instead.[48]

The symptoms of this higher form of the disease include loss of the brain's ability to control the movement of muscles, tremors, and

cardiac arrhythmia.[49] and the lack of muscular control.[50]

Relapsing anti-NMDAR encephalitis

Atypical Anti-NMDA receptor encephalitis (a kind of Autoimmune encephalitis) can appear in the form of relapsing optic neuritis.[51][failed verification][non-primary source needed]

Variants still idiopathic

Apart from the previously cited spectrums (

Anti-MOG, and Anti-NF
) there is a long list of MS variants, with possibly different pathogenesis, which are still idiopathic and considered inside the MS-spectrum.

Pseudotumefactive variants

Most atypical variants appear as tumefactive or pseudotumefactive variants (lesions whose size is more than 2 cm (0.79 in), with mass effect, oedema and/or ring enhancement)[52][53] Some cases of the following have shown anti-MOG auto-antibodies and therefore they represent MS cases only partially.[citation needed]

Atypical lesion location variants

Also the location of the lesions can be used to classify variants:

Myelocortical multiple sclerosis

Myelocortical multiple sclerosis (MCMS), proposed variant with demyelination of spinal cord and cerebral cortex but not of cerebral white matter [61] Several atypical cases could belong here. See the early reports of MCMS<[62][63]

AQP4-negative Optic-spinal MS

Real Optic-spinal MS (OSMS) without anti-AQP4 antibodies, has been consistently reported, and it is classified into the MS spectrum.[64][65]

OSMS has its own specific immunological biomarkers[66] The whole picture is under construction and several reports exists about overlapping conditions.

Pure spinal MS

Pure spinal multiple sclerosis: Patients with clinical and paraclinical features suggestive of cord involvement of multiple sclerosis (MS)-type albeit not rigidly fulfilling the McDonald criteria[67] Some inflammatory conditions are associated with the presence of scleroses in the CNS.[68] Optic neuritis (monophasic and recurrent) and Transverse myelitis (monophasic and recurrent)

LHON associated MS

LHON associated MS (LHON-MS), a presentation of LHON with MS-like CNS damage, and therefore a subtype of MS according to McDonalds definition.[10]

Atypical OCB variants

Also different classifications by body fluid biomarkers is possible:

  • Oligoclonal negative MS: Some reports point to the possibility of a different pathogenesis[69] They represent around 5% of the cases[70] which is suspected to be immunogenetically different.[71] Their evolution is better than standard MS patients,[72]
  • Oligoclonal IgM positive MS, with immunoglobulin-M Bands (IgM-Bands), which accounts for a 30-40% of the MS population and has been identified as a predictor of MS severity.[73] It has been reported to have a poor response to interferon-beta but a better response to glatimer acetate instead[74]
  • OCB's types: OCBs are made up of activated B-cells. It seems that the molecular targets for the OCB's are patient-specific.[75]

Radiologically atypical variants

Inside well defined MS (Lesions disseminated in time and space with no other explanation) there are atypical cases based in radiological or metabolic criteria. A four-groups classification has been proposed:[76]

  • Tumefactive demyelinating lesion (TDL)-onset MS
  • Acute disseminated encephalomyelitis (ADEM)-like MS
  • vanishing white matter disease[77]
  • Leukodystrophy-like MS.

Other radiological classification of atypical lesions proposes the following four subtypes:[78]

  • infiltrative
  • megacystic
  • Baló-like
  • ring-like lesions

Atypical clinical courses

In 1996, the US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis (ACCTMS) standardized four clinical courses for MS (Remitent-Recidivant, Secondary Progressive, Progressive-Relapsing and Primary progressive). Later,[79] some reports state that those "types" were artificially made up trying to classify RRMS as a separate disease so that the number of patients was low enough to get the interferon approved by the FDA under the orphan drugs act.[79] Revisions in 2013 and 2017 removed the Progressive-Relapsing course and introduced CIS as a variety/course/status of MS, establishing the actual classification (CIS, RRMS, SPMS and PPMS). Nevertheless, these types are not enough to predict the responses to medications and several regulatory agencies use additional types in their recommendations lide Highly active MS, Malignant MS, Aggressive MS or Rapidly progressive MS.[80]

Highly Active MS

As of 2019, HAMS is defined as an RRMS phenotype with one or more of the following characteristics:[80]

  1. DSS scale of 4 points at 5 years of onset of the disease
  2. Multiple relapses (two or more) with incomplete recovery in the ongoing year
  3. More than 2 brain magnetic resonance imaging (MRI) studies demonstrating new lesions or increase in the size of the lesions in T2, or lesions that enhance with gadolinium despite treatment (Clinical case 1 and 2).
  4. No response to treatment with one or more DMTs for at least one year.

There is a group of patients who have defined clinical and radiological risk factors that predict a behavior of greater risk of conversion to HAMS, without having the diagnostic criteria of HAMS in a first clinical attack have predictors of high risk.

Some other previous authors have used other definitions like:

  • High activity according to 2017 definition of activity
  • Rapid accumulation of physical and cognitive deficit, despite treatment with DMT's.
  • Being eligible for immunoablative therapy followed by autologous haematopoietic stem cell transplantation (aHSCT) because of a) the failure of conventional treatment, b) frequent and severe (disabling) relapses, or c) MRI activity (new T2 or gadolinium-enhancing lesions).

Malignant MS

See malignant multiple sclerosis

Occasionally, the term ‘malignant’ MS (MMS) has been used to describe aggressive phenotypes of MS, but this is another ambiguous term that—despite wide usage—means different things to different people.

In 1996, the US National MS Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis, “malignant MS” was also included, namely, “disease with a rapid progressive course, leading to significant disability in multiple neurologic systems or death in a relatively short time after disease onset.”[full citation needed]

Many authors[who?] reserve the term malignant for fulminant forms of MS that deteriorate so rapidly from the outset as to be almost monophasic, and result in death within months to a few years. One such example is the Marburg variant of MS, which is classically characterized by extensive necrotic and/or tumefactive lesions with mass effect.

Despite recent (and increasing) emphasis on early detection of patients with aggressive MS, the original definition of MMS was not modified by the NMSS Advisory Committee in its latest publication in 2013 (Lublin et al., 2014).[full citation needed]

Aggressive MS

Common to all definitions is the early, unexpected acquisition of disability followed by frequent relapses and highly active disease seen on MRI.

One definition can be based on EDSS score and the time to develop secondary progressive MS (SPMS) (Menon et al., 2013).[full citation needed]

No consensus exists on the speed of progression or degree of disability sufficient for aggressive MS, but some assume that reaching an EDSS score of 6 points probably represents an upper limit beyond which the risk-benefit ratio for an aggressive treatment is unfavourable.[citation needed]

Pragmatically, AMS has been defined as any type of MS that is associated with repeated severe attacks and accelerated accrual of disability—put more simply, "rapidly progressive" MS.

Rapidly progressive multiple sclerosis

This kind of MS was previously reported to behave different that the standard progressive course,

plasma exchange[83]

In very rapidly progressive multiple sclerosis the use of immunosuppressive therapy (mitoxantrone/cyclophosphamide), rituximab, autologous haematopoietic stem cell therapy or combination therapy should be considered carefully.[84]

Under research

Some auto-antibodies have been found consistently across different MS cases but there is still no agreement on their relevance:

Other auto-antibodies can be used to stablish a differential diagnosis from very different diseases like Sjögren syndrome which can be separated by Anti–Calponin-3 autoantibodies.[101]

The correlation between this genetic mutation and MS was challenged but in 2018 has been replicated by an independent team.[102] Notice that this results do not refer to general MS.

In general, NMO-like spectrum without known auto-antibodies is considered MS. Principal component analysis of these cases show 3 different kinds of antibody-negative patients. The metabolite discriminators of RRMS and Ab-NMOSD suggest that these groupings have some pathogenic meaning.[103]

As MS is an active field for research, the list of auto-antibodies is not closed nor definitive. For example, some diseases like

NMDAR Anti-NMDA receptor encephalitis.[54]

Venous induced demyelination has also been proposed as a hypothetical MS variant produced by

chronic fatigue syndrome).[106]

Also

Adrenomyeloneuropathy could be in the list. Specially interesting is X-linked adrenoleukodystrophy (X-ALD or CALD).[107]

Genetic types

Different behaviour has been reported according to the presence of different HLA genes.

HLA DRB3*02:02 patients

In

DRB3 cases, autoimmune reactions against the enzyme GDP-L-fucose synthase has been reported[108][109]
The same report points that the autoimmune problem could derive from the gut microbiota.

HLA-DRB1*15:01 has the strongest association with MS.[110]

HLA-DRB1*04:05, HLA-B*39:01, and HLA-B*15:01 are associated with independent MS susceptibility and HLA-DQβ1 position 9 with phenylalanine had the strongest effect on MS susceptibility.[110]

Another possible type is one with auto-antibodies against

DRB3*02:02 patients, autoimmune reactions against the enzyme GDP-L-fucose synthase has been reported[108][109]
The same report points that the autoimmune problem could derive from the gut microbiota.

Rapidly progressive multiple sclerosis

See malignant multiple sclerosis

This is a specially aggressive clinical course of progressive MS[111] that has been found to be caused by a special genetic variant. It is due to a mutation inside the gene NR1H3, an arginine to glutamine mutation in the position p.Arg415Gln, in an area that codifies the protein LXRA.[112]

Primary progressive variants

Some researchers propose to separate primary progressive MS from other clinical courses. PPMS, after recent findings seem to point that it is pathologically a very different disease.[113][114][115][116][non-primary source needed]

Some authors think since long ago that primary progressive MS should be considered a disease different from standard MS,[117][118] and it was also proposed that PPMS could be heterogeneous[119]

Clinical variants have been described. For example, Late Onset MS.[120][111] It is due to a mutation inside the gene NR1H3, an arginine to glutamine mutation in the position p.Arg415Gln, in an area that codifies the protein LXRA.


For the rest of the progressive cases, it has been found that the lesions are diffuse instead of the normal focal ones,[121] and are different under MR spectroscopy.[122] RRMS and PPMS patients also show differences on the retinal layers yields examined under OCT.[123]

Some authors have proposed a dual classification of PPMS, according to the shape of edges of the scars, in MS-like and ADEM-like

Secretogranin II and Protein 7B2, in CSF can be used to separate RRMS from PPMS[125]

Recently, the hypothesis of PPMS being apart from RRMS/SPMS is taken further credibility due that it was shown that CSF from PPMS patients can carry the disease to other animals, producing neurodegeneration in mice[113] and that Normal Appearing White Matter (NAWM) structure is also different[126][non-primary source needed]

The predominant lesions in PPMS are slowly expanding lesions with T cells, microglial, and macrophage-associated demyelination in close similar to pattern I demyelination[127]

As of 2019 it has been found that the profile of T-cells is different in PPMS and SPMS[128][non-primary source needed]

Clinical situations inside standard MS

MS can be considered among the acquired demyelinating syndromes with a multiphasic instead of monophasic behaviour.[129] Multiple sclerosis has a prodromal stage in which an unknown underlying condition, able to damage the brain, is present, but no lesion has still developed.

MS is usually classified in clinical types, though they are unrelated to the underlying pathology. Some critical reports say that the current "types" were artificially made up, just to treat RRMS as a separate disease. In this way the number of patients was low enough to enter the orphan drugs act, and get the interferon approved by the FDA under this schema.[79] Recent reviews state that all types are a mixture of inflammation and neurodegeneration, and that all types should be considered the same disease.[130]

Other possible clinical courses are:

Preclinical MS: CIS and CDMS

The first manifestation of MS is the so-called Clinically isolated syndrome, or CIS, which is the first isolated attack. The current diagnosis criteria for MS do not allow doctors to give an MS diagnosis until a second attack takes place. Therefore, the concept of "clinical MS", for an MS that can be diagnosed, has been developed. Until MS diagnosis has been established, nobody can tell whether the disease one is dealing with is MS.[citation needed]

Cases of MS before the CIS are sometimes found during other neurological inspections and are referred to as subclinical MS.[131] Preclinical MS refers to cases after the CIS but before the confirming second attack.[132] After the second confirming attack the situation is referred to as CDMS (clinically defined multiple sclerosis).[133]

CIS itself is sometimes considered itself as a disease entity, different from MS. Even if they share the same underlying condition CIS is not MS given that it lacks the presence of lesions.[134] Approximately 84% of the subjects with CIS experience a second clinical demyelinating event and are diagnosed with clinically definite MS (CDMS) within 20 years.

RIS, subclinical, silent and prodromal MS

See also Radiologically isolated syndrome

Silent MS has been found in autopsies before the existence of MRI

clinical definitions" cannot be applied to around 25% of the MS cases.[136]
Currently a distinction is made between "silent" and subclinical.

In absence of attacks, sometimes a radiological finding suggestive of demyelination (T2 hyperintensities[137]) can be used to establish a pre-diagnosis of MS. This is often named "Radiologically Isolated Syndrome" (RIS). Cases before the first attack or CIS are subclinical in the sense that they do not produce clinical situations.

If a second radiological event appears without clinical consequences, the clinical situation is named "Silent MS" (Okuda criteria).[138] Anyway, it is reported that all MS cases have an active subclinical phase before the CIS[139]

It has been noted that some aspects of the MS underlying condition are present in otherwise healthy MS patients' relatives,[140] suggesting a wider scope for the "silent MS" term.

In these cases Interleukin-8 is a risk for clinical conversion.[141] It has also been proposed that always exists a subclinical phase in the beginning of every MS case, during which the permeability of the BBB can be used for diagnosis[142]

It is also under investigation whether MS has a

non-specific symptoms. Some reports point to a prodrome of several years for RRMS and decades for PPMS.[143][144][145]

Aggressive multiple sclerosis

Relapsing-Remitting MS is considered aggressive when the frequency of exacerbations is not less than 3 during 2 years. Special treatment is often considered for this subtype.[146] According to these definition aggressive MS would be a subtype of RRMS.

Other authors disagree and define aggressive MS by the accumulation of disability, considering it as a rapidly disabling disease course[147] and therefore inside PPMS.

The aggressive course is associated to grey matter damage and meningeal inflammation, and presents a special intrathecal (meninges and CSF) inflammatory profile.[148]

After the 2016 revision of the MS phenotypes, it is called Highly active multiple sclerosis[80]

Mitoxantrone was approved for this special clinical course. Some reports point to Alemtuzumal being beneficial.[149]

Pediatric and pubertal MS

MS cases are rare before puberty, but they can happen. Whether they constitute a separate disease is still an open subject. Anyway, even this pubertal MS could be more than one disease, because early-onset and late-onset have different demyelination patterns.[150]

Pediatric MS patients tend to have active inflammatory disease course with a tendency to have brainstem / cerebellar presentations at onset. Due to efficient repair mechanisms at early life, pediatric MS patients tend to have longer time to reach EDSS 6 but reach it at earlier age.[151]

An iron-responsive variant of MS has been reported in children.[152]

Controversy for the definition

Given that the etiology of MS is unknown, the current definitions of MS are all based on its appearance.[medical citation needed] The most commonly used definition, the McDonald criteria, requires just the presence of demyelinating lesions separated in space and time, together with the exclusion of every known demyelinating condition.[medical citation needed] However as of 2023 most current MRI machines only pick up 60% of MS lesions, and even 7T machines only pick up 85%. The MS of MS people not discovered by MRI is found only in autopsy.[153]

This unspecific definition has been criticized. For some people this has turned MS into a heterogeneous condition with several underlying problems.[154] Besides, the complementary problem also exists. Given that McDonalds-MS is based just in the distribution of the lesions, even twins with the same underlying condition can be classified different[155]

Finally, the "exclusion of every other known disease" condition also creates problems. Rightfully classified MS patients can be rightfully classified out of the spectrum when their particular underlying problem is discovered. For example,

neuromyelitis optica was previously considered MS and currently is not, even if it appears that the MS definition has not changed.[medical citation needed
]

Currently there is no single diagnosis test for MS that is 100% sensitive and specific.[156][157]

Pathological and clinical definitions

McDonald criteria propose a clinical diagnosis based on a pathological definition, saying that the focus for diagnosis "remains on the objective demonstration of dissemination of lesions in both time and space" (DIT and DIS). But given that other diseases produce similar lesions, it is also required that those lesions cannot be explained by any other known disease.[citation needed]

This open definition present problems.[158] For example, before the discovery of anti-AQP4 in 2006, most optic-spinal MS patients were classified rightfully as MS. Currently they are classified as NMO. Both diagnosis are correct even though the definition has not (apparently) changed.

According to some pathologists, a pathological definition is required because clinical definitions have problems with differential diagnosis[43] and they always use a pathological definition on articles about post-mortem retrospective diagnosis, but for practitioners that need a diagnosis as soon as possible MS is often regarded as a pure clinical entity, defined simply by a positive result in the standard clinical case definition being then named "clinically definite MS" (CDMS, Poser) or simply "MS" (McDonald).[159]

Both definitions lead to different results. For example, confluent subpial cortical lesions are the most specific finding for MS, being exclusively present in MS patients.[160] but can only be detected post-mortem by an autopsy[161] Therefore, any other diagnosis method will have false positives.

Other meanings of MS

There is no known etiology for MS and therefore no etiology-based definition is possible. Comparison to a post-mortem retrospective diagnosis is possible, but useless to practitioners and short-term researchers, and it is not usually done. Therefore, all meanings for the words "Multiple Sclerosis" are somehow diffuse.[citation needed]

The pathological definition based on proven dissemination in time and space has problems. For example, it leaves situations like RIS (radiologically isolated syndrome) outside the MS spectrum because the lack of proof, even in the case that this condition later could shown the same pathogenic conditions than MS cases.[162]

Besides, usually the term "multiple sclerosis" is used to refer to the presence of the unknown underlying condition that produces the MS lesions instead to the mere presence of the lesions. The term MS is also used to refers to the process of developing the lesions.[163]

Some authors instead speak about the biological disease vs. its clinical presentation.[164]

Anyway, the precise meaning in each case can be normally deduced from the context.

Handling several clinical definitions

Given that several definitions of MS coexist, some authors are referring to them using whether CDMS for Poser positives, or McDonalds-MS with a prefix for McDonalds positives, including the release year in the prefix.[165]

CIS and conversion to MS

The 2010 revision of the McDonald criteria[166] allows the diagnosis of MS with only one proved lesion (CIS). Consistently, the later revision for the MS phenotypes in 2013 was forced to consider CIS as one of the MS phenotypes.[167]

Therefore, the former concept of "Conversion from CIS to MS", that was declared when a patient had a second MS attack, does not apply anymore. More accurate is now to speak about conversions from the CIS phenotype to other MS phenotype.[168]

See also

References

  1. PMID 28987175
    .
  2. ^ "Find out more about demyelinating diseases, including multiple sclerosis". Mayo Clinic. Retrieved 2022-06-23.
  3. PMID 11787357
    .
  4. S2CID 17386506
    .
  5. S2CID 44411472
    .
  6. ISBN 978-1-85317-506-0
    .
  7. S2CID 219199163
    .
  8. PMID 29064441
    .
  9. PMID 30893099
    .
  10. ^
    S2CID 38817368
    .
  11. ^
    PMID 28337644
    .
  12. PMID 28761905
    .
  13. S2CID 45173537
    .
  14. S2CID 49310332
    .
  15. PMID 24415568
    .
  16. S2CID 30860834
    .
  17. ^
    PMID 25917068
    .
  18. S2CID 22270592
    .
  19. ^ Wingerchuk D (2006). "Neuromyelitis Optica (Devic's Syndrome)" (PDF). 2006 Rare Neuroimmunologic Disorders Symposium. Archived from the original (PDF) on 2006-09-25. Retrieved 2007-01-05.
  20. PMID 21532234
    .
  21. PMID 25889963
    .
  22. ^
    PMID 25815356
    .
  23. ^
    PMID 27458601
    .
  24. ^
    S2CID 7219279
    .
  25. doi:10.1016/S1090-3798(15)30066-0
    .
  26. S2CID 1387384
    .
  27. PMID 30487359
    .
  28. S2CID 70688931
    .
  29. S2CID 54126682
    .
  30. PMID 26185777
    .
  31. PMID 31736862
    .
  32. ISSN 0028-3878
    .
  33. PMID 26920678
    .
  34. S2CID 146038130
    .
  35. ^
    PMID 30582947
    .
  36. S2CID 29204735
    .
  37. ^ "Progressive MS: a new perspective | Multiple Sclerosis Society UK". www.mssociety.org.uk. Archived from the original on 2007-06-21.
  38. PMID 31921355
    .
  39. PMID 27840642
    .
  40. ^
    PMC 5782583
    .
  41. ^
    PMID 26637427
    .
  42. S2CID 203654410
    .
  43. ^
    PMID 20129937
    .
  44. PMID 31845616
    .
  45. PMID 30788836
    .
  46. PMID 33026456
    .
  47. PMID 20129932
    .
  48. PMID 7629530
    .
  49. ^ "Cardiac arrythmia". health-cares.net. Archived from the original on 6 March 2016.
  50. ^ "Multiple sclerosis - Symptoms and causes". Mayo Clinic. Retrieved 2022-06-24.
  51. PMID 30787630
    .
  52. PMID 18535080
    .
  53. PMID 14684539
    .
  54. ^
    S2CID 26341166
    .
  55. PMID 24094691
    .
  56. PMID 15514902
    .
  57. S2CID 38765870
    .
  58. S2CID 52859541
    .
  59. PMID 22826546
    .
  60. S2CID 17631796
    .
  61. PMID 30143361
    .
  62. ^ Vignos MC (2016). A histopathological and magnetic resonance imaging assessment of myelocortical multiple sclerosis: A new pathological variant (Ph.D. thesis). Kent State University. Archived from the original on 2022-10-29. Retrieved 2022-06-24.
  63. S2CID 208628537
    .
  64. S2CID 237636213
    .
  65. S2CID 19372571
    .
  66. doi:10.26650/experimed.2018.18002
    .
  67. S2CID 21709554
    .
  68. ISBN 978-1-4160-6068-0. Archived from the original
    (PDF) on 2015-08-24. Retrieved 2015-01-14.
  69. S2CID 214428195
    .
  70. S2CID 22724352
    .
  71. S2CID 21855273
    .
  72. PMID 8558146
    .
  73. S2CID 49347759
    .
  74. S2CID 46954452
    .
  75. PMID 32084151
    .
  76. S2CID 58550590
    .
  77. ^
    S2CID 3917307
    .
  78. S2CID 28377856
    .
  79. ^
    PMID 30300457
    .
  80. ^
    S2CID 73460639
    .
  81. S2CID 43651011
    .
  82. PMID 23991165
    .
  83. ^ Seidi O (January 27, 2015). The Role of Therapeutic Plasma Exchange in Clinical Neurology (Report). Archived from the original on June 21, 2021. Retrieved July 13, 2016 – via khartoumspace.uofk.edu.
  84. S2CID 10805065
    .
  85. S2CID 246866517
    .
  86. PMID 22784115
    .
  87. PMID 24032025
    .
  88. PMID 23732997
    .
  89. PMID 26862169
    .
  90. PMID 31375628
    .
  91. S2CID 210193928
    .
  92. PMID 28283100
    .
  93. S2CID 199036968. Archived from the original
    on 2019-04-23. Retrieved 2019-04-23.
  94. S2CID 52175657
    .
  95. PMID 27656661
    .
  96. PMID 26290755
    .
  97. PMID 31731780
    .
  98. PMID 24086369
    .
  99. S2CID 266111836
    .
  100. PMID 32358523
    .
  101. S2CID 13693467
    .
  102. S2CID 44082278
    .
  103. PMID 31659123
    .
  104. PMID 31842151
    .
  105. S2CID 16896871
    .
  106. ^ "Chronic Fatigue Syndrome - Symptoms, Diagnosis, Treatment of Chronic Fatigue Syndrome". Health Information. New York Times. The following test results... are seen consistently...: Brain MRI showing swelling in the brain or destruction of part of the nerve cells (demyelination)
  107. PMID 34137074
    .
  108. ^ a b "Link Between Gut Flora and Multiple Sclerosis Discovered". Neuroscience News. 2018-10-11. Retrieved 2022-06-29.
  109. ^
    S2CID 52959112
    .
  110. ^
    PMID 31382992
    .
  111. ^
    PMID 27253448
    .
  112. PMID 27253441
    .
  113. ^
    S2CID 21263405
    .
  114. S2CID 58984399
    .
  115. S2CID 236819936
    .
  116. S2CID 266118700
    .
  117. S2CID 19215860
    .
  118. S2CID 71465403
    .
  119. S2CID 16397501
    .
  120. S2CID 78885337. Archived from the original
    on 2022-01-27. Retrieved 2022-01-27.
  121. S2CID 27178351
    .
  122. S2CID 24226475
    .
  123. S2CID 7737278
    .
  124. S2CID 23522920
    .
  125. PMID 25098164
    .
  126. S2CID 81874161
    .
  127. PMID 28620346
    .
  128. PMID 31474991
    .
  129. PMID 25381299
    .
  130. PMID 30687321
    .
  131. S2CID 27212599
    .
  132. S2CID 11750372
    .
  133. S2CID 27303451
    .
  134. PMID 30022111
    .
  135. PMID 6054893
    .
  136. S2CID 21581253
    .
  137. PMID 29157404
    .
  138. PMID 23886745
    .
  139. PMID 30945591
    .
  140. S2CID 41756033
    .
  141. S2CID 22377941
    .
  142. PMID 26187333
    .
  143. ^ Cortese M (2017-12-18). Marianna, The timing of environmental risk factors and prodromal signs of multiple sclerosis (Ph.D. thesis).
  144. PMID 34155379
    .
  145. S2CID 204887642
    .
  146. PMID 20037526
    .
  147. S2CID 205516534
    .
  148. S2CID 5042430
    .
  149. S2CID 208228516
    .
  150. S2CID 24065442
    .
  151. PMID 29523094
    .
  152. PMID 30963028
    .
  153. ^ Will Brown, Cambridge University, 7.00 min, https://www.youtube.com/watch?v=EQxQoCqifRM&t=206s
  154. S2CID 71379237
    .
  155. S2CID 78597245
    .
  156. PMID 26149978
    .
  157. S2CID 23435315
    .
  158. PMID 29143579
    .
  159. S2CID 13870943
    .
  160. S2CID 25337149
    .
  161. S2CID 38379112
    .
  162. PMID 29157404
    .
  163. PMID 16948216
    .
  164. PMID 25381299
    .
  165. PMID 30635483
    .
  166. PMID 21387374
    .
  167. PMID 24871874
    .
  168. S2CID 24039151
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Inflammatory_demyelinating_diseases_of_the_central_nervous_system&oldid=1212569490"